RxDoctor Payments Data

Ahmed Rashed, MD

Interventional Cardiology · Lapeer, MINPI 1851656755

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 55 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$237
  • Novartis$236
  • Siemens Medical Solutions USA, Inc.$137
  • AstraZeneca$127
  • Amgen$101
  • Abbott$88
  • plus $315 from 11 others

What the payments were for

  • Travel & lodging$635%
  • Food & beverage$1,16494%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 10th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$316,351
Medicare patients
313
Services billed
4,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$128,508
EntrestoSacubitril/Valsartan29$33,411
XareltoRivaroxaban22$13,407
Ranolazine ErRanolazine12$3,192
ClopidogrelClopidogrel Bisulfate101$2,091
Atorvastatin Calcium113$1,469
Prasugrel Hcl16$1,417
Metoprolol Succinate60$1,127
Metoprolol Tartrate100$819
Spironolactone56$597
Carvedilol63$557
Losartan Potassium34$497
Amiodarone Hcl29$463
Ezetimibe25$426
Amlodipine Besylate46$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$128,508124 claims
NovartisEntresto$236$33,41129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Lapeer

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →